Want to see JP:4577 full AI Analyst Report?
4577 Stock Chart & Stats
¥1356.00
-¥13.00(-0.64%)
At close: 4:00 PM EST
¥1356.00
-¥13.00(-0.64%)
Day’s Range― - ―
52-Week Range¥1,120.00 - ¥1,521.00
Previous CloseN/A
Volume21.10K
Average Volume (3M)65.99K
Market Cap
¥37.65B
Enterprise Value¥43.09K
Total Cash (Recent Filing)¥954.00M
Total Debt (Recent Filing)¥9.29B
Price to Earnings (P/E)12.1
Beta0.24
Next Earnings
Oct 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.07%
Share Statistics
EPS (TTM)107.46
Shares Outstanding28,854,880
10 Day Avg. Volume72,300
30 Day Avg. Volume65,993
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.65
Price to Sales (P/S)0.68
P/FCF Ratio6.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)91.5
Revenue Forecast (FY)¥54.50B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and a substantial equity buffer reduce financial risk and preserve flexibility. This should help Daito withstand demand or pricing volatility and continue investing in pharmaceutical manufacturing capabilities without excessive balance-sheet strain.
Improved Cash GenerationThe return to positive operating and free cash flow strengthens internal funding capacity. If sustained, this can support investment, debt management and shareholder returns while reducing reliance on external financing.
Positive Operating ProfitabilityDaito continues to generate positive earnings from its pharmaceutical manufacturing activities despite weaker conditions than in prior peak years. Maintaining positive operating margins provides a foundation for recovery if contracted production volumes improve.
Bears Say
Sharp Revenue ContractionA large top-line decline signals weaker production volumes, contract mix or customer demand and can reduce operating leverage. Sustained contraction would constrain growth, utilization and the company’s ability to rebuild prior profitability levels.
Profitability Below Prior PeaksMargin deterioration indicates that recent earnings are less robust than during the company’s stronger period. Lower profitability reduces resilience to cost inflation or pricing pressure and makes a durable earnings recovery dependent on improved mix or utilization.
Inconsistent Cash ConversionAlthough cash flow recently turned positive, conversion remains moderate and working-capital or timing effects appear to weigh on cash realization. The multi-year history of negative free cash flow means durability of the improvement is not yet established.
Daito Pharmaceutical Co., Ltd. News
4577 FAQ
What was Daito Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Daito Pharmaceutical Co., Ltd. lowest stock price was ¥1120.00 and its highest was ¥1521.00 in the past 12 months.
What is Daito Pharmaceutical Co., Ltd.’s market cap?
Daito Pharmaceutical Co., Ltd.’s market cap is ¥37.65B.
When is Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Daito Pharmaceutical Co., Ltd.’s upcoming earnings report date is Oct 08, 2026 which is in 31 days.
How were Daito Pharmaceutical Co., Ltd.’s earnings last quarter?
Daito Pharmaceutical Co., Ltd. released its earnings results on Jul 10, 2026. The company reported ¥30.96 earnings per share for the quarter.
Is Daito Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Daito Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Daito Pharmaceutical Co., Ltd. pay dividends?
Daito Pharmaceutical Co., Ltd. pays a Semiannually dividend of ¥22.5 which represents an annual dividend yield of 3.07%. See more information on Daito Pharmaceutical Co., Ltd. dividends here
What is Daito Pharmaceutical Co., Ltd.’s EPS estimate?
Daito Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daito Pharmaceutical Co., Ltd. have?
Daito Pharmaceutical Co., Ltd. has 28,854,880 shares outstanding.
What happened to Daito Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Daito Pharmaceutical Co., Ltd. reported an EPS of ¥30.96 in its last earnings report. Following the earnings report the stock price went up 0.241%.
Which hedge fund is a major shareholder of Daito Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4577
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daito Pharmaceutical Co., Ltd.
Daito Pharmaceutical Co.,Ltd. is a global entity primarily involved in the creation and sale of a diverse range of pharmaceutical products. Their offerings span active pharmaceutical ingredients (APIs) and chemical intermediates, alongside both prescription and over-the-counter (OTC) medications, and home-delivered medicines. These products are available in various formats, including tablets, capsules, lozenges, granules, and powdered forms. Beyond its own brand, the company also provides contract manufacturing services, developing medicinal formulations for other pharmaceutical firms. Additionally, Daito Pharmaceutical markets health food products. Established in 1942, it was initially known as Daito Corporation, changing to its current name in 1992, and maintains its headquarters in Toyama, Japan.
Technical Analysis
Fuji Pharma Co., Ltd.
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―